Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-2-27
pubmed:abstractText
Common polymorphisms in genes encoding phase I and phase II enzymes are considered to modify lung cancer risk due to changes in enzyme activity. Candidates include genetic variants of glutathione S-transferases (GSTM1, GSTT1 and GSTP1) and myeloperoxidase (MPO). We performed a large case-control study of these candidate genes in 1103 patients with non-small cell lung cancer (NSCLC) and 627 controls without NSCLC. Associations between deletion genotypes of GSTM1 and GSTT1 and between single nucleotide polymorphisms (SNPs) of GSTP1 Ile105Val and MPO G-463A were first tested by adjusted logistic regression. Then we analysed gene-gene interactions, also incorporating our published data on the Ile462Val SNP in the phase I enzyme, cytochrome P450 CYP1A1. The homozygous GSTP1 105Val genotype was significantly under-represented in NSCLC compared with controls (OR = 0.73; 95%CI 0.53-1.00; P = 0.050), especially in females (OR = 0.57; 95%CI 0.34-0.98; P = 0.04). The GSTT1-null genotype was significantly over-represented in adenocarcinomas (OR = 1.41; 95%CI 1.06-1.90; P = 0.02) but not in squamous cell carcinomas (OR = 1.03; 95%CI 0.76-1.41; P = 0.84). There was weak risk reduction associated with GSTM1 null in heavy smokers (OR = 0.71; 95%CI 0.54-0.94; P = 0.02), but neither GSTM1 nor MPO genotypes affected the overall risk of NSCLC. The MPO and CYP1A1 risk genotypes interacted to increase the overall risk of NSCLC (OR = 2.88; 95%CI 1.70-5.00; P < 0.001). The data are consistent with the concept that multiple genes of modest effect interact to confer genomic-based susceptibility to lung cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0143-3334
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
525-32
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16195240-Adenocarcinoma, pubmed-meshheading:16195240-Aged, pubmed-meshheading:16195240-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:16195240-Carcinoma, Squamous Cell, pubmed-meshheading:16195240-Case-Control Studies, pubmed-meshheading:16195240-Cytochrome P-450 CYP1A1, pubmed-meshheading:16195240-Female, pubmed-meshheading:16195240-Genetic Predisposition to Disease, pubmed-meshheading:16195240-Genotype, pubmed-meshheading:16195240-Glutathione Transferase, pubmed-meshheading:16195240-Humans, pubmed-meshheading:16195240-Lung Neoplasms, pubmed-meshheading:16195240-Male, pubmed-meshheading:16195240-Middle Aged, pubmed-meshheading:16195240-Odds Ratio, pubmed-meshheading:16195240-Peroxidase, pubmed-meshheading:16195240-Polymorphism, Single Nucleotide, pubmed-meshheading:16195240-Smoking
pubmed:year
2006
pubmed:articleTitle
CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung.
pubmed:affiliation
Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't